Taking a molecule from discovery to clinical development to commercialization requires the right combination of promising compound, specialized scientific expertise and sufficient funding. To assemble these elements, we've implemented a variety of business models and deal structures that promote both partnership and productivity:
- Fee for Service: This includes purchasing raw materials and outsourcing for specific studies or services.
- Asset Purchase/Sale: Lilly acquires ownership (possibly still engaging partner in the project) or Lilly relinquishes ownership and control upon sale.
- Co-development: These deals are designed around shared investment and/or distribution of work.
- Risk-sharing: This occurs when the partner or Lilly assumes some level of risk and often includes a future option to acquire an asset or technology.
- Equity/Spin-outs: These deals establish an ownership position around a broader set of activities (i.e., a portfolio or company).
Regardless of deal structure, the goal is the same: innovate more efficiently and more effectively. By leveraging our combined assets, expertise and capabilities, we can lower costs, increase productivity and, ultimately, produce a medicine that helps patients.
In addition to traditional partnerships with Lilly, we find and facilitate innovation through Lilly Ventures and Lilly Asian Ventures. These two funds invest in start-up biopharmaceutical and medical technology companies via early through expansion-stage investments.
For more information on our integrated alliance management products and services, please contact us at Partnering@lilly.com.